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Abstract
Background—The quality of medication use in older adults is a recurring problem of substantial
concern. Efforts to both measure and improve the quality of medication use often define quality too
narrowly and fall short of addressing the complexity of an older adult's medication regimen.
Objective—In an effort to more comprehensively define the quality of medication use in older
adults, we conducted a prospective cohort study to: 1) describe the quality of medication use in
community-residing older adults at baseline, examining differences between Whites and African
Americans; 2) examine the effect of race on medication-related problems[mtr1], and 3) assess the
change in quality medication use between Whites and African Americans over time. This paper
presents the research design and methods of this longitudinal study.
Methods—We interviewed 100 White and 100 African-American community-residing older adults
three times over one year (baseline, 6, and 12 months). We oversampled African Americans so that
we could estimate racial differences in the quality of medication use. We collected information on
the quality of medication use, relying on a clinical pharmacist's assessment of quality and the
Assessing Care of Vulnerable Elders (ACOVE) quality indicators. We also collected data on
demographic characteristics, health literacy, functional status, and participant-reported drug therapy
concerns.
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Results—Two hundred older adults were enrolled into the study and completed a baseline visit. Of
the 200, 92% completed the 6-month visit (n=183) and 88% completed the 12-month visit (n=176).
We present baseline demographic characteristics for the 200 older adults enrolled in the study.
Conclusion—This longitudinal study is an initial step toward developing more comprehensive,




The Institute of Medicine (IOM) and other prominent organizations have recognized that
medication-related problems plague our health care system.(1-3) Nowhere are medication
problems more pronounced than in older adults.(4) The elderly are at an increased risk of
developing medication-related problems due to their chronic disease burden, multiple
prescribers, and concurrent medication use, which may compromise their health status,
functional status, and quality of life.(5-7) The costs attributed to the use of potentially
inappropriate medications in the elderly are projected to average $7.2 billion annually.(8)
Moreover, the costs associated with drug-related morbidity and mortality are staggering,
estimated in one study to be $177 billion annually, with nearly half ($80 billion) in ambulatory
care.(9-11)
The IOM definition of quality care can be adapted to define quality medication use: “the degree
to which medication use for individuals and populations increases the likelihood of desired
health outcomes and is consistent with current professional knowledge.”(12,13) Similarly,
quality problems related to medication use can be classified broadly as: underuse (i.e., failure
to provide a medication when it could have produced a favorable outcome for a patient);
overuse (i.e., when a medication is provided under circumstances in which the potential for
harm exceeds the possible benefit or when there is no clear benefit); and misuse (i.e., when an
appropriate medication has been selected but a preventable problem occurs that precludes the
patient from realizing the full potential benefit of the medication).
Most efforts to measure and improve the quality of medication use target specific drugs,
specific medication-related problems, or specific diseases, rather than the patient. These
approaches too narrowly define the quality of medication use and cannot account for the
complexity of an older adults' medication needs. For example, the Beers criteria, explicit
criteria for identifying potentially inappropriate medications in the elderly, focus only on
appropriate prescribing of select, high-risk medications in older adults. (14) Although
important, the Beers criteria alone are insufficient to assess an individual's quality of
medication use if the goal is to account for the unique medication needs of individual patients.
The Medication Appropriateness Index (MAI) and the Assessing Care of Vulnerable Elders
(ACOVE) quality indicators appear to be the most comprehensive measures of appropriate
medication use, although they measure very different constructs of medication quality. (15,
16) The MAI assesses medication appropriateness for each medication a patient is taking, while
the ACOVE quality indicators measure appropriateness of select medications and compliance
with important medication-related processes of care that impact quality, such as appropriate
medication documentation and medication monitoring. Neither instrument, however, accounts
for both the unique medication needs of an individual and gaps in medication-related processes
of care that often lead to medication-related problems. For this reason, we conducted an implicit
review of the quality of medication use in older adults over time. This implicit assessment by
a clinical pharmacist will allow us to obtain a more comprehensive assessment of quality
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medication use that is unique to the medication needs of each individual patient. (17,18) The
pharmacist's clinical assessment was guided by a list of potential medication-related problems,
which was developed based on an extensive review of the literature. The list took into account
the Beers criteria, important elements of medication appropriateness identified in the MAI, and
processes of care such as medication access, documentation, and monitoring that have been
shown to impact the quality of medication use. (14-16,19,20). The list of potential medication-
related problems was developed with the goal of refining it based on our experience and study
findings.
Although it is unknown what impact race may have on the quality of medication use, it has
been suggested that racial differences exist in medication use and access to care. (21) For
example, it is well documented that African American older adults have lower total drug
spending, use fewer prescription medications, and have higher rates of nonadherence than
Whites. (22,23) To further explore this potential relationship, we have oversampled race in our
study to examine its effect on the quality of medication use in older adults.
Achieving quality medication use requires more than prescribing the right drug in the right
dose to the right person—it will require measures and interventions that are tailored to the
individual's needs and the multiple medications he/she is taking and address medication-related
processes of care that enable quality medication use. In an effort to more comprehensively
define the quality of medication use in older adults, we conducted a prospective cohort study
to: 1) describe the quality of medication use in community-residing older adults at baseline,
examining differences between Whites and African Americans; 2) examine the effect of race
on medication-related problems, testing the hypothesis that race is an independent predictor of
medication-related problems, and 3) assess the change in quality medication use between
Whites and African Americans over time, testing the hypothesis that the number of medication-
related problems will remain unchanged over the one year study. [MR2]This paper presents the
research design and methods of this longitudinal study.
Subjects and Methods
Overview
We interviewed 100 White and 100 African-American older adults residing in the community
three times (baseline, 6, and 12 months); we oversampled African Americans so that we could
estimate racial differences in the quality of medication use. We collected information on the
quality of medication use, relying on a clinical pharmacist's assessment of quality and an
evaluation of quality medication use using the Assessing Care of Vulnerable Elders (ACOVE)
quality indicators.(16) We also collected data on demographic characteristics, health literacy,
functional status, and participant-reported drug therapy concerns. The study protocol was
approved by the University of North Carolina at Chapel Hill School of Medicine Institutional
Review Board.
Inclusion and Exclusion Criteria
Participants had to meet all of the following inclusion criteria: (a) age ≥ 60 years, (b) residing
independently in the community setting; (c) taking ≥3 regularly-scheduled prescription and/or
non-prescription medications (d) able to read and speak English, (e) willing to participate, as
indicated by providing informed consent and HIPAA-compliant authorization for release of
medical information. Participants were excluded if they had ≥3 errors on the cognitive
screening instrument (24) or received clinical pharmacy services within the past 6 months.
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Participants were recruited from the Orange County Department on Aging Eldercare Program
and two senior housing complexes. The Eldercare Program is staffed by licensed clinical social
workers and an occupational therapist and provides case management to nearly 300 older
persons residing independently in their own homes, apartments, or senior housing. Eldercare
provides information and support to the individual and their caregivers to maximize the older
persons' independence, enhance quality of life, and facilitate adjustment to age-related changes.
The two senior housing complexes involved in the study are affiliated with the Eldercare
program.
Participant Recruitment
Using the Eldercare Program contact list, the study pharmacist conducted a screening telephone
call with each older adult to describe the study and invite them to participate in a baseline visit
for verification of eligibility and enrollment of qualified individuals. All baseline study visits
were scheduled within two weeks of the screening call. Individuals recruited from area senior
housing complexes were volunteers who responded to posted flyers and advertisements about
the study. This method of recruitment was used in addition to Eldercare to reach our anticipated
enrollment goals. All participants were compensated $20 per visit for the baseline, 6-, and 12-
month interviews (maximum $60).
Baseline Visit
For individuals expressing an interest in participating in the study, the pharmacist arranged a
time to meet with the individual in their home to discuss the study, administer the 6-item
cognitive screen, obtain informed consent and HIPAA-compliant authorization for release of
medical information, verify eligibility, and enroll eligible individuals into the study. Cognitive
status was assessed using a 6-item screen to identify older persons with probable cognitive
impairment. (24) This screening test, which can be administered face-to-face in only 1-2
minutes, relies on a 3-item recall and a 3-item temporal orientation. Individuals with probable
cognitive impairment (≥3 errors) were excluded; this cut-off previously demonstrated a
sensitivity of 89% and specificity of 88% for a diagnosis of dementia, which is comparable to
the Mini-Mental State Examination.(25)
Informed consent and authorization to release medical information were obtained on all
individuals meeting eligibility criteria. The pharmacist then conducted the baseline interview.
Measures (described below) included demographics, health literacy, functional status, drug
therapy concerns, and clinical pharmacist assessment of quality medication use, including the
ACOVE quality indicators. The data collection schedule for each instrument is presented in
Table 1.
Health Literacy was assessed using the Short-Test of Functional Health Literacy in Adults (S-
TOFHLA).(26) The S-TOFHLA measures a patient's ability to read and understand health-
related material. It is comprised of 4 numeracy items and 2 prose passages (36 items) and takes
about 12 minutes to administer. Scores range from 0 to 36 and are categorized as inadequate
(0-16), marginal (17-22), or adequate health literacy (23-36). Patients with inadequate health
literacy often misread simple materials, such as prescription bottles, appointment slips, or
nutrition labels; persons with marginal health literacy frequently have trouble with more
complex materials, such as an educational brochure or informed-consent document.(27,28)
Functional Status was assessed via self-report using an 8-item instrumental activities of daily
living (IADL) scale.(29) This widely-used scale assesses complex self-maintenance skills in
older adults, including the ability to use a telephone, shop, prepare food, complete housework,
do laundry, utilize public transportation, administer medication, and handle financial
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responsibilities. Each task is scored as 0 (independence), 1 (some assistance required), or 2
(complete dependence on others). Items are summed (maximum=16) to compute an IADL total
score, with higher scores reflecting poorer functional status.
Drug Therapy Concerns contains 25 items related to patients' concerns in 5 areas: (1) perceived
efficacy of therapy; (2) adverse drug reactions; (3) overmedication concerns; (4) adherence
issues; and (5) knowledge. In initial research in the elderly, each subscale exhibited an
acceptable level of reliability.(30) Validity of the subscales was demonstrated by correlations
with a measure of overall medication satisfaction.
Clinical Pharmacist Assessment of Quality Medication Use—The pharmacist's
assessment of quality medication use relied on a three-step implicit process. In contrast to an
explicit review, which relies on predetermined criteria that are insensitive to the unique
medication regimens of individual patients, an implicit review allows for the pharmacist to
integrate all available information about a patient and arrive at an assessment of quality
medication use. (17,18) Although judgments may be influenced by the pharmacist's experience,
consistency, and attention to detail, an implicit review allows the pharmacist to make
assessments of quality medication use that are patient-centered and account for an individuals'
medication-related needs. Based on the results from our longitudinal study, we hope to develop
a more structured implicit review process for use in subsequent studies. For purposes of this
longitudinal study, the three-step implicit process involved: 1) a comprehensive medication
review with the older adult, 2) a medical record review, and 3) formulation of an assessment
of quality medication use. Each of these steps is described in greater detail.
The Comprehensive Medication Review: During the interview, the pharmacist recorded the
following information: 1) medical conditions; 2) all medications, including prescription, over-
the-counter, and complementary and alternative medications; 3) medication-taking behaviors;
4) medication allergies and adverse drug events; 5) method of payment for medications,
including prescription drug insurance or assistance; 6) dispensing pharmacy; 7) use of
medication adherence aids, including pill boxes, medication calendars or lists, and caregivers;
8) estimated out-of-pocket spending per month on medications; and 9) additional medication-
related information provided by the individual. This information will be used in describing the
population but is also critical in assessment of quality medication use.
The Medical Record Review: After completing the baseline visit, the pharmacist contacted
the physician's office where the medical record was located, submitted documentation of
participant consent to release information, and arranged a time to review the medical record at
the office. During the medical record review, the pharmacist abstracted information on
medications, medical conditions, laboratory values, physician assessment of the individual's
medical conditions, hospitalizations, and any other information pertinent to assessing the
individual's quality of medication use. Using the medical record, the pharmacist also completed
an assessment of quality medication use by applying the Assessing Care of Vulnerable Elders
(ACOVE-2) Quality Indicators.(31) The ACOVE Project, a collaboration between RAND
Health and Pfizer, Inc., led to the development of the first quality-of-care assessment system
for older persons (ACOVE), with a set of quality indicators specific to medication use.(16)
The original set of ACOVE quality indicators was updated in 2001 (ACOVE-2); ACOVE-2
was the version used at all three visits for all participants throughout our longitudinal study.
(31) ACOVE-2 consists of 39 quality indicators of medication use categorized in 4 domains:
1) prescribing indicated medications; 2) avoiding inappropriate medications; 3) education,
continuity, and documentation; and 4) medication monitoring. Two of the 39 ACOVE-2 quality
indicators were excluded from our study because they targeted hospitalized patients. The
ACOVE indicators have excellent face validity due to the expert consensus process used in
their development.
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The Formulation of an Assessment of Quality Medication Use: The pharmacist has been
trained extensively in assessing drug therapy in the older adult population. The pharmacist's
evidence-based clinical assessment relied on data from the comprehensive medication review
with the participant, the medical record review, and the published literature, including clinical
practice guidelines and geriatric prescribing guidelines. The medication review provided an
opportunity for the pharmacist to gather participant-reported information about current
medication use, medical conditions, and other medication-related findings and inspect
participant pill bottles. The medical record review provided information regarding medical
history, medications, laboratory values, and other pertinent information that only the physician
and other health care professionals can provide. Finally, the published literature, including
clinical practice guidelines and geriatric prescribing guidelines, provided the pharmacist with
evidence upon which to base clinical assessments.
In this study, the pharmacist's assessments were guided by a list of potential medication-related
problems developed by study investigators following an extensive review of the literature.
(14,15,19,31-36) The eight potential medication-related problems and their accompanying
definitions are listed in Table 2. We provided the pharmacist with an open-ended selection in
the event a potential medication-related problem was identified that could not be classified
according to the list. In addition to identifying the type of medication-related problem, the
pharmacist recorded a subcategory for each problem along with additional notes regarding the
problem. A sample list of subcategories for each problem was available to the pharmacist with
the option of also creating their own subcategory as needed. The list of potential medication-
related problems was developed with the goal of refining it based on our experience and study
findings. We used two methods to assess nonadherence: a clinical pharmacist assessment of
adherence (i.e., adherent, nonadherent) for each medication a person was taking (Table 3) and
a validated patient self-report measure.(37) Because no gold standard exists for measuring
nonadherence, we relied on multiple methods of assessment.(38-40) Upon completion of the
baseline visit, all baseline data was entered into the study database by the research assistant.
(Figure 1)
The study pharmacist did not intervene on any potential medication-related problem at any
point throughout the study unless deemed to be life-threatening. In addition, the pharmacist
only responded to participant questions regarding their medications when asked. Pharmacist
responses to participant inquiries were considered standard of care and only occurred if the
participant posed a question. The study team developed guidelines for addressing life-
threatening medication-related problems during the study, which were presented to the IRB,
refined based on feedback, and approved as part of the study protocol. The guidelines stated
that if a life-threatening medication-related problem was detected during the in-home interview
and the medication-related problem warranted immediate attention, clinical judgment would
be exercised by the pharmacist in determining when to call 911 versus contacting the study
physician and principal investigator to discuss the most appropriate action to be taken. All of
this occurred while the study pharmacist was present in the home with the participant. If a
medication-related problem was identified after the pharmacist had left the participant's home
(i.e., through medical record review) and thought to be of a serious nature, the same procedure
for contacting the study physician and principal investigator was followed. In addition, the
study pharmacist contacted the participant's primary physician, as necessary, to have the
individual's medications modified accordingly. The IRB-approved guidelines included in our
study protocol provided examples of medication-related problems considered life-threatening.
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Examples of medication-related problems considered life-threatening and,
therefore, warranting intervention
• Medications that are absolutely contraindicated in a participant based on prescribing
guidelines (e.g., metformin in severe renal failure).
• Medical conditions that warrant immediate attention and intervention based on
medical care standards (e.g., the participant with severe chest pain or shortness of
breath who needs to seek immediate medical help; hypertensive urgencies and
hypertensive emergencies as defined in the The Seventh Report of the Joint National
Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC 7).
• Adverse drug events that are causing the participant immediate and life-threatening
harm (e.g., a beta blocker that is contributing to a significant drop in heart rate and
causing severe dizziness and lightheadedness)
• Nonadherence to a medication that could be considered life-threatening (e.g.,
nonadherence to warfarin in a participant with deep vein thrombosis)
Examples of medication-related problems not considered life-threatening and,
therefore, not warranting intervention
• Drugs that are potentially inappropriate in the elderly, but not absolutely
contraindicated (e.g., benzodiazepines, propoxyphene)
• Medical conditions that are undertreated (e.g., hypertension, hyperlipidemia,
diabetes), in that blood pressure, lipids, and blood sugars are not at goal, but also are
not causing immediate, life-threatening complications.
• Nonadherence with a medication regimen that is not immediately life threatening
(e.g., nonadherence to an antihypertensive or nonadherence to a diabetes medication
that is causing blood pressure or blood sugars to be poorly controlled, but at a level
that does not warrant immediate attention.)
Based on time spent by the pharmacist in subject recruitment, enrollment, and follow-up in
addition to her other responsibilities outside of the study, it was determined, within several
months of starting the study, that a second study pharmacist would be needed to meet our
projected enrollment numbers and complete the study in a timely manner. The second
pharmacist joined the study team in October 2005, participated in education and training
regarding the study, and enrolled her first participant in December 2005.
To assess inter-rater reliability, the second clinical pharmacist conducted an independent
assessment of quality medication use on a random sample of participants seen by the primary
study pharmacist (n=20). To determine physician agreement with the clinical assessments, a
physician reviewed the assessments of quality medication use made by the clinical pharmacist
for the random sample of 20, indicating whether the assessments appear valid and warrant
attention.
Six- and Twelve- Month Visits
We conducted 6- and 12-month interviews and medical record reviews with all participants
using virtually the same measures as at baseline (Table 1). All follow-up visits had to be
scheduled within 6-weeks preceding or following the expected 6- and 12-month visit. In
completing the assessments of quality medication use at 6 and 12 months, the pharmacist
conducting the assessment did not refer to her previous assessments of quality medication use.
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We assessed health care utilization during the study year at the 12-month visit. Specifically,
the pharmacist elicited from the participant information regarding visits over the previous year
to urgent care and the emergency room as well as admissions to a hospital, assisted living
facility, and long-term care facility. This information was verified by the pharmacist through
medical record review. The pharmacist also asked about falls during the past year. All data
were entered into the database by the research assistant; we re-entered baseline, 6-, and 12-
month data for a random sample of 20% of the participants to insure accuracy of data entry.
Sample Size and Planned Statistical Analyses
The sample size estimation for our study was based on confidence interval widths and detecting
meaningful differences between Whites and African Americans in the proportion of individuals
with at least one medication-related problem at baseline. A sample size of 100 per group met
the conservative np ≥ 10 or n(1-p) ≥ 10 “sufficiently large” criterion where n=sample size and
p=prevalence of at least one medication-related problem allowing the use of the normal
distribution for calculation of confidence intervals.(41) This sample size resulted in 95%
confidence interval half-widths of 6%-10% for prevalences ranging from 10%-90% and
provided 80% power to detect absolute differences of at least 14%-21% between Whites and
African Americans depending on the prevalences in the two groups (α=0.05). Using the number
of medication-related problems and a Poisson regression power analysis, we would have 80%
power to detect a difference of at least 17% in the rate of medication-related problems between
Whites and African Americans assuming the average number of medication-related problems
in Whites was 6 (α=0.05).(42,43)
Analyses
In this paper, we present demographic and baseline characteristics of our sample. However,
we have outlined our planned analyses for subsequent papers. For our first objective, we will
describe the quality of medication use among White and African American community
dwelling older adults. This begins with descriptive statistics within each race group as well as
comparisons between the races. Our primary variable of interest, medication-related problems,
will be analyzed as both categorical variables (present or not by type) and as count data (total
number of problems). Chi-square tests for independence and count data regression models will
be used to compare these outcomes between White and African American older adults.
Associations between other variables such as health literacy and functional status with
medication-related problems will be investigated using correlations and regression models that
are appropriate for the distributions of the variables being compared (e.g., continuous normal,
discrete ordinal, binary data). These analyses will be conducted within each race group then
combined if the relationship is found to be consistent by testing interaction terms in
multivariable models.
Second, we will test the hypothesis that race is an independent predictor of number of
medication-related problems, controlling for factors such as age, number of medications,
health literacy, functional status and drug therapy concerns. We will also evaluate the quality
of medication use using the set of explicit quality indicators developed in the ACOVE project.
(31) We will analyze the data in a similar way to the work of Higashi et al.(4) Quality scores
are calculated as the proportion of eligible patients who receive indicated care. This is reported
as pass rates for each quality indicator for which an individual was eligible. The indicators are
classified in 4 domains, with overall pass rates for each domain calculated and compared.
Our final goal is to assess the change in quality medication use over time. To do so, the
prevalence and number of medication-related problems in total and by type will be reported at
each time point (6 and 12 months). We also plan to estimate the incidence of new medication-
related problems (overall and by type) at 6 months and 12 months by tracking the number of
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new medication-related problems that have occurred since the last assessment as well as the
persistence of problems (i.e., problems present at baseline or 6 months that remain unresolved
at 6 or 12 months, respectively). We will test the following hypothesis: the number of
medication-related problems will remain unchanged over the one year study, specifically 6
months compared to baseline and 12 months compared to baseline. The goal of the longitudinal
analysis is to assess the stability (or change) in quality medication use over time and any factors
that are associated with worsening of medication-related problems. We will use mixed model
methodology to look at the effect of time (baseline, 6 and 12 months), type of problem, and
any covariates that are found to be significant in predicting medication-related problems at
baseline. Mixed models account for the intra-person correlation of data from the multiple time
points and allow estimation of the variability of change over time across individuals. Knowing
the stability of medication-related problems (or lack thereof) and important risk factors of
instability will be critical for planning intervention trials designed to improve the quality of
medication use in older adults.
Results
Progress to Date
The first participant was enrolled in April 2005, and we completed enrollment in August 2006.
A total of 435 older adults were recruited for participation in the study to reach an enrollment
of 200 older adults (100 Whites, 100 African Americans) (Figure 2). All participants were
followed for 12 months, with the last visit completed in August 2007. Of the 200 older adults
completing a baseline visit, 92% completed the 6-month visit (n=183) and 88% completed the
12-month visit (n=176). Baseline demographic characteristics for the 200 older adults enrolled
in the study are presented in Table 4. On average the participants were over 75 years of age,
predominantly female, and used more than 10 medications. We anticipate that the results of
this study will be reported at a later time.
Discussion
The quality of health care in the United States continues to fall short of expectations. A
contributing factor is the suboptimal use of medications; a problem that is causing significant
morbidity and mortality and costing the healthcare industry billions of dollars each year. The
quality of medication use is a particular problem among older Americans. In an observational
cohort study it was found that the quality of pharmacologic care provided to older adults ranged
from 10% to 100% (avoiding inappropriate medications (97%); prescribing indicated
medications (50%); patient education, continuity and documentation (81%); and medication
monitoring (64%)).(4) This study highlights the range of medication-related problems affecting
the quality of care of older adults.
Efforts to measure and improve the quality of medication use in older adults have traditionally
focused on specific problems (e.g., inappropriate drugs and doses), pre-determined
combinations of medication-related problems, or individual diseases (even when patients have
multiple chronic conditions). While these issues are important, they fail to take into account a
more patient-centered perspective that considers the overall quality of medication use.
Although current measures have substantially advanced our ability to both understand and
assess the quality of medication use in older adults, they too have limitations. For example,
the Beers criteria, while relatively easy to apply, too narrowly define quality, focusing only on
the use of inappropriate medications in the elderly.(14) The Medication Appropriateness Index
(MAI) substantially broadens the scope of assessing medication appropriateness by rating each
medication a patient is taking, but may not account for all elements important to quality
medication use.(15) And, while the ACOVE quality indicators include medication-related
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processes of care (e.g., monitoring, documentation), they were not intended to assess the quality
of medication use at the level of the individual.(16,31)
Our current longitudinal study seeks to extend these approaches to measuring the quality of
medication use. Notably, we have designed our measures to provide the basis for intervening
with elderly patients to improve the quality of medication use. Although the pharmacist's
assessment is guided by a list of potential medication-related problems, ultimately the quality
assessment is determined based on the unique medication needs of the participant after a
thorough interview and medical record review. Limitations inherent in our approach include
the implicit assessment of quality medication use as determined by the clinical pharmacist and
the lack of physician-pharmacist collaboration in arriving at the final assessment. However,
we believe this is an initial and necessary exploratory step toward better defining the elements
of quality medication use at the level of the patient.
Conclusions
Strategies to better measure and improve the quality of medication use in older adults are
needed. This longitudinal study is part of a larger research agenda in which we seek to build a
more comprehensive, patient-centered measure of quality medication use and develop and test
interventions to improve the quality of medication use and health outcomes for older adults.
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Figure 1. Sample Data Screen from Study Database
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Figure 2. Subject Recruitment, Enrollment and Follow-Up
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Baseline 6 months 12 months
Demographic Characteristics X
Short-Test of Functional Health Literacy in Adults (S-
TOFHLA)
X
Drug Therapy Concerns X X X
Instrumental Activities of Daily Living Scale X X X
Clinical Pharmacist Assessment of Quality Medication Use X X X
ACOVE-2 Quality Indicators of Medication Use X X X
Healthcare Utilization X
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Table 2
Framework for Assessing the Quality of Medication Use
Potential Medication-Related Problem Definition
Suboptimal Drug† The individual is receiving a drug that has no indication, is not effective, or is potentially
not safe (i.e., risk of using drug outweighs benefit).
Suboptimal Dosing or Duration The individual is taking an appropriate medication, but the dose, duration, or frequency is
not optimal to achieve desired response, or has the potential for harm.
Adverse Drug Events The individual is experiencing adverse consequences attributed to a drug or the inappropriate
use of a drug.
Nonadherence†† The individual has not filled a prescription, is not taking a drug, or is not using a drug as
prescribed, whether intentional or unintentional.
Drug Not Cost Effective The individual is prescribed a medication for which a less costly, equally effective and safe
drug is available, and preferred by the patient, but the patient is receiving a more expensive
product; or the patient could benefit from enrollment in a prescription drug program, but is
not receiving the benefit and desires to.
Undertreatment The individual has a medical condition that requires drug therapy (clear indication) and the
patient has no contraindications to the drug, but the drug was not prescribed.
Inadequate medication monitoring The individual is receiving a drug and monitoring is required to assess response to therapy
or ensure safety, but has not been done.
Other (Potential Medical or Drug Therapy
Problem)
The individual is receiving a drug for which there is a potential medication-related problem
that cannot be categorized as one of the above problems.
†
Problems, such as drug-drug, drug-food, and drug-disease interactions, when encountered, were classified as Suboptimal Drug, with a subcategory
designation indicating a drug interaction. For this reason, a separate medication-related problem for Drug Interactions was not developed.
††
Table 3 provides detail regarding the pharmacist's assessment of nonadherence used in this study.
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Table 3
Pharmacist Clinical Assessment of Adherence
The pharmacist, in meeting with the older adult, begins by having the individual explain how he/she uses each medication and the indication for each
medication. Following the individual's explanation, the pharmacist asks the older adult a series of questions to determine whether the individual is likely
adhering to the medication as prescribed. Following each question, the pharmacist inquires further to gather more information, as needed. Examples of
questions include:
• In the past 2 weeks how many times have you missed taking a dose of this medication?
• In the past 4 weeks how many times have you missed taking a dose of this medication?
• Have you missed any doses in the last week?
• Overall, do you think you have taken your medication as prescribed?
In addition to the questions, the pharmacist also:
1 Inspects the medication bottles and pill boxes to assess the amount of medication remaining based on prescription fill date.
2 Inquires about reasons for not taking the medication as prescribed.
3 Assesses individual response to the medication through evaluation of medical conditions, laboratory values, or other signs or symptoms.
4 Examines the extent to which factors such as cost, access, cognition, polypharmacy, regimen complexity and other factors may impact ones
ability to adhere to their prescribed regimen.
The pharmacist, taking into account all of the above, arrives at an implicit, clinical assessment of adherence (i.e., adherent, nonadherent) for each
medication a person is taking. This results in multiple responses for each older adult with the total number of responses (medications) varying across
individuals. We sum these binary variables and globally define adherence per person as the proportion of adherent medications out of the total medications
prescribed, with ≥80%=adherent and <80%=nonadherent.(44) Additional analyses will be conducted to further explore rates of nonadherence (e.g.,
based on type of medication used, comparing various methods of assessment of adherence).
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Table 4
Demographics and Baseline Characteristics (N=200)
Whites (N=100) African Americans (N=100) P-value
Age (mean, SD) 78.3 (8.2); range 62 – 96 75.5 (8.5); range 60-95 0.017




 Never Married 3 8
 Other 0 4
Female (%) 72 81 NS
Education (highest level completed,%) <0.001
 Some College or Technical School 24 12
 Postgraduate 23 4
 High School Graduate 21 35
 College Graduate 18 6
 Elementary 8 24
 Some High School 6 19
Physicians, (mean, SD) 3.6 (1.8); range 1 – 9 2.8 (1.5); range 0-8 <0.001
Living Alone (%) 64 49 0.032
Medications† (mean, SD) 11.6 (5.0); range 3-26 9.7 (4); range 4-21 0.003
Chronic Conditions†† (mean, SD) 8.4 (3.1); range 2 - 19 7.4 (2.8); range 2-18 0.014
Pharmacies (mean, SD) 1.3 (0.57); range 1 – 3 1.3 (0.5); range 1-3 NS
Has Help with Medications (%) 16 16 NS
Uses Medication Aid (%)††† 70 57 0.056
 Pill Box 47 50 NS
 Written List of Medications 30 16 0.019
 Other 16 6 0.024
Shows Written List to Physician (%) 18 11 NS
Has Some Form of Prescription (%)
Drug coverage
91 94 NS
Could Not Purchase Meds Due to Cost
(%)
12 28 0.005
Monthly Medication Expenses (%) 0.009
 <$100 46 65
 $100 - $249 30 27
 $250 - $499 16 4
 $750 - $999 2 0
 Don't Know 6 4
Time Spent Interviewing Minutes
(mean, SD)
83.8 (20.9);range 50-165 78.8 (14.9); range 45-135 0.050
Time Acquiring Medical Record in
Days (mean, SD)
4.2 (4.9);range 0- 28 4.2 (4.9); range 0-23 NS
Time Reviewing Records and
Formulating Assessments in Minutes
(mean, SD)
91.2 (60.7);range 0- 270 97.8 (53); range 0-255 NS
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Whites (N=100) African Americans (N=100) P-value
†
Includes prescription, over-the-counter, and complementary and alternative medications.
††
Defined as any chronic condition documented in the medical record.
†††
Do not total 100% since individuals could have reported use of more than one medication aid.
NS=Not Significant
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